Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137042 | 0.98 | ALDH1A1 (0.69) | ALDH1A1KMT2APOLBCA12CA1 | |
| SCHEMBL11009084 | 0.92 | ALDH1A1 (0.67) | ALDH1A1KMT2APOLBCA12CA1 | |
| SCHEMBL12296988 | 0.91 | ALDH1A1 (0.65) | ALDH1A1KMT2APOLBCA12CA1 | |
| Hydrochloric Acid SCHEMBL18128494 | 0.88 | KMT2A (0.60) | ALDH1A1KMT2APOLBCA12CA1 | |
| SCHEMBL467176 | 0.86 | — | — | |
| SCHEMBL25009512 | 0.86 | ALDH1A1 (0.80) | ALDH1A1KMT2APOLBCA12CA1 | |
| SCHEMBL27090339 | 0.86 | ALDH1A1 (0.80) | ALDH1A1KMT2APOLBCA12CA1 | |
| Bromide SCHEMBL28651634 | 0.84 | ALDH1A1 (0.60) | ALDH1A1KMT2APOLBCA12CA1 | |
| SCHEMBL8540879 | 0.84 | ALDH1A1 (0.77) | ALDH1A1KMT2APOLBCA12CA1 | |
| SCHEMBL32685227 | 0.84 | ALDH1A1 (0.77) | ALDH1A1KMT2APOLBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240392273-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-3624846-B1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY INCLUDING A COMBINATION OF NICOTINIC ACID AND TRYOPTOPHAN | BHAMIS RES LABORATORY PVT LTD (IN) | 2024-08-07 | — | — | EP | disclosed |
| EP-4401758-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | Takeda Pharmaceutical Company Limited (JP) | 2024-07-24 | — | — | EP | disclosed |
| EP-4403187-A2 | LIQUID PROTEIN FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | Eagle Biologics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240181063-A1 | Liquid Protein Formulations Containing Viscosity-Lowering Agents | EAGLE BIOLOGICS, INC. | 2024-06-06 | — | — | US | disclosed |
| CN-118139636-A | Delivery of promoted concentrated antibody formulations using hyaluronidase | 武田药品工业株式会社 | 2024-06-04 | — | — | CN | disclosed |
| EP-3791862-B1 | LIQUID PROTEIN FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | EAGLE BIOLOGICS INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-11 | — | — | US | disclosed |
| US-11738082-B2 | High concentration protein formulations with reduced viscosity | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2023-08-29 | — | — | US | disclosed |
| WO-2023042096-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | WO | disclosed |
| EP-2670765-B1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| EP-3200804-A1 | POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | Eagle Biologics, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-3043775-A2 | LIQUID PROTEIN FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | Arsia Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| WO-2016054259-A1 | POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | Arsia Therapeutics, Inc. (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2015038818-A2 | LIQUID PROTEIN FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | Arsia Therapeutics, Inc. (US) | 2015-03-19 | — | — | WO | disclosed |
| US-20150071925-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | EAGLE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-8846647-B2 | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738082-B2 | High concentration protein formulations with reduced viscosity | ALB, TTR, MAX | CA2 3794/4885ALDH1A1 4823/4885KMT2A 4024/4885 |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | CA2 3794/4885ALDH1A1 4823/4885KMT2A 4024/4885 |
| US-20150071925-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | ALB, PDE8A, IGFBP1 | CA2 4774/4885ALDH1A1 4435/4885KMT2A 4492/4885 |
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, CDK17 | CA2 4687/4885ALDH1A1 1833/4885KMT2A 4424/4885 |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | CA2 4687/4885ALDH1A1 2193/4885KMT2A 4371/4885 |
| US-20240181063-A1 | Liquid Protein Formulations Containing Viscosity-Lowering Agents | ALB, PDE8A, IGFBP1 | CA2 4774/4885ALDH1A1 4435/4885KMT2A 4492/4885 |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | CA2 4687/4885ALDH1A1 2193/4885KMT2A 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.